Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)
Taiwan
· Delayed Price · Currency is TWD 80.70
-0.40 (-0.49%)
Apr 29, 2026, 1:30 PM CST
Foresee Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 431.27 | 418.69 | 195.04 | 301.51 | 226.03 | Upgrade
|
| Revenue Growth (YoY) | 3.01% | 114.67% | -35.31% | 33.39% | -1.91% | Upgrade
|
| Cost of Revenue | 137.06 | 178.89 | 81.07 | 25.54 | 50.95 | Upgrade
|
| Gross Profit | 294.22 | 239.8 | 113.97 | 275.97 | 175.08 | Upgrade
|
| Selling, General & Admin | 181.4 | 147.32 | 160.16 | 124.23 | 99.07 | Upgrade
|
| Research & Development | 975.13 | 1,172 | 961.44 | 621.18 | 614.64 | Upgrade
|
| Operating Expenses | 1,157 | 1,320 | 1,122 | 745.41 | 713.71 | Upgrade
|
| Operating Income | -862.32 | -1,080 | -1,008 | -469.44 | -538.63 | Upgrade
|
| Interest Expense | -5.57 | -6.71 | -2.85 | -0.4 | -0.68 | Upgrade
|
| Interest & Investment Income | 18.17 | 28.28 | 23.53 | 8.34 | 3.53 | Upgrade
|
| Currency Exchange Gain (Loss) | -17.67 | 21.51 | -2.32 | 23.35 | -3.05 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.17 | 3.26 | 0.83 | 1.2 | 10.17 | Upgrade
|
| EBT Excluding Unusual Items | -858.2 | -1,033 | -988.45 | -436.96 | -528.66 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 0.29 | 0.8 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.03 | -0.2 | -0.31 | -0.13 | Upgrade
|
| Asset Writedown | - | - | - | -1.16 | - | Upgrade
|
| Other Unusual Items | - | 0.28 | 0.01 | - | - | Upgrade
|
| Pretax Income | -858.2 | -1,033 | -988.64 | -438.13 | -527.99 | Upgrade
|
| Income Tax Expense | 24.95 | 47.87 | 47.67 | 34.51 | 41.28 | Upgrade
|
| Net Income | -883.15 | -1,081 | -1,036 | -472.64 | -569.27 | Upgrade
|
| Net Income to Common | -883.15 | -1,081 | -1,036 | -472.64 | -569.27 | Upgrade
|
| Shares Outstanding (Basic) | 155 | 137 | 127 | 118 | 117 | Upgrade
|
| Shares Outstanding (Diluted) | 155 | 137 | 127 | 118 | 117 | Upgrade
|
| Shares Change (YoY) | 12.80% | 7.89% | 7.82% | 0.57% | 15.74% | Upgrade
|
| EPS (Basic) | -5.70 | -7.87 | -8.14 | -4.00 | -4.85 | Upgrade
|
| EPS (Diluted) | -5.70 | -7.87 | -8.14 | -4.00 | -4.85 | Upgrade
|
| Free Cash Flow | -845.19 | -1,323 | -933.84 | -291.29 | -220.19 | Upgrade
|
| Free Cash Flow Per Share | -5.46 | -9.64 | -7.34 | -2.47 | -1.88 | Upgrade
|
| Gross Margin | 68.22% | 57.27% | 58.44% | 91.53% | 77.46% | Upgrade
|
| Operating Margin | -199.95% | -257.90% | -516.63% | -155.70% | -238.30% | Upgrade
|
| Profit Margin | -204.78% | -258.20% | -531.33% | -156.76% | -251.86% | Upgrade
|
| Free Cash Flow Margin | -195.98% | -316.07% | -478.80% | -96.61% | -97.42% | Upgrade
|
| EBITDA | -812.19 | -1,016 | -950.68 | -429.72 | -498.38 | Upgrade
|
| EBITDA Margin | -188.32% | -242.56% | - | -142.52% | -220.50% | Upgrade
|
| D&A For EBITDA | 50.13 | 64.2 | 56.95 | 39.72 | 40.24 | Upgrade
|
| EBIT | -862.32 | -1,080 | -1,008 | -469.44 | -538.63 | Upgrade
|
| EBIT Margin | -199.95% | -257.90% | - | -155.70% | -238.30% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.